International Dermatology Outcome Measures (IDEOM): Report from the 2020 Annual Meeting-Reference-Cited by-同舟云学术

International Dermatology Outcome Measures (IDEOM): Report from the 2020 Annual Meeting

Published:2021-09-17 Issue: Volume: Page:1-8
ISSN:1018-8665
Container-title:Dermatology
language:en
Short-container-title:Dermatology

Author:

Kohn Alison H.,Alavi Afsaneh,Armstrong April W.,Babalola Folawiyo,Garg Amit^ORCID,Gottlieb Alice B.,Grilli Lesley,Jemec Gregor Borut Ernst^ORCID,Latella John,Marcus Kendall,Merola Joseph F.,Ortega-Loayza Alex G^ORCID,Siegel Daniel M.,Strand Vibeke,Tan Jerry K.L.,Perez-Chada Lourdes M.

Abstract

Background: The International Dermatology Outcome Measures (IDEOM) initiative is a non-profit organization that aims to develop evidence-based outcome measurements to evaluate the impact of treatments for patients with dermatological disease. IDEOM includes all key stakeholders in dermatology (patient, physician, industry, insurer, and government) during the process of developing such outcome measurements. Summary: Here, we provide an update of IDEOM activities that were presented at the 2020 IDEOM Virtual Annual Meeting (October 23–24, 2020). During the meeting, multiple IDEOM workgroups (psoriasis, psoriatic arthritis, hidradenitis suppurativa, acne, pyoderma gangrenosum, and actinic keratosis) shared their progress to date, as well as future directions in developing and validating Patient-Reported Outcome Measures. Updates on demonstrating efficacy in clinicals trials by the US Food and Drug Administration are also summarized. Key Messages: In this report, we summarize the work presented by each IDEOM workgroup (psoriasis, psoriatic arthritis, hidradenitis suppurativa, acne, pyoderma gangrenosum, and actinic keratosis) at the 2020 IDEOM Virtual Annual Meeting.

Publisher

S. Karger AG

Subject

Dermatology

Reference18 articles.

1. Gottlieb AB, Levin AA, Armstrong AW, Abernethy A, Duffin KC, Bhushan R, et al. The International Dermatology Outcome Measures Group: formation of patient-centered outcome measures in dermatology. J Am Acad Dermatol. 2015;72(2):345–8.

2. Boers M, Beaton DE, Shea BJ, Maxwell LJ, Bartlett SJ, Bingham CO, et al. OMERACT Filter 2.1: elaboration of the conceptual framework for outcome measurement in health intervention studies. J Rheumatol. 2019;46(8):1021–7.

3. Beaton DE, Maxwell LJ, Shea BJ, Wells GA, Boers M, Grosskleg S, et al . Instrument selection using the OMERACT Filter 2.1: the OMERACT methodology. J Rheumatol. 2019;46(8):1028–35.

4. Gottlieb AB, Armstrong AW, Christensen R, Garg A, Duffin KC, Boehncke WH, et al. The International Dermatology Outcome Measures initiative as applied to psoriatic disease outcomes: a report from the GRAPPA 2013 meeting. J Rheumatol. 2014;41(6):1227–9.

5. Salame N, Perez-Chada LM, Singh S, Callis Duffin K, Garg A, Gottlieb AB, et al. Are your patients satisfied a systematic review of treatment satisfaction measures in psoriasis. Dermatology. 2018;234(5–6):157–65.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of DermSat-7 for Assessing Treatment Satisfaction in Patients with Acne;JAMA Dermatology;2024-01-01

2. Eligibility Criteria for Active Ulcerative Pyoderma Gangrenosum (PG) in Clinical Trials: A Delphi Consensus on Behalf of the Understanding PG: Review and Assessment of Disease Effects (UPGRADE) Group;Journal of Investigative Dermatology;2023-12

3. Practical aspects of the diagnosis and management of pyoderma gangrenosum;Frontiers in Medicine;2023-02-14

4. Current and emerging biologic and small molecule systemic treatment options for psoriasis and psoriatic arthritis;Current Opinion in Pharmacology;2022-12

5. International Dermatology Outcome Measures (IDEOM): Report from the 2021 Annual Meeting;Journal of Drugs in Dermatology;2022-07-01